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ABSTRACT 
EVALUATION OF LIVER TRANSPLANT PRIORITIZATION METHODS  
FOR HEPATOCELLULAR CARCINOMA PATIENTS  
USING MULTISTATE MODELS 
Sarah K. Alver 
November 18, 2015 
 The Model for End Stage Liver Disease (MELD), used for prioritizing liver 
transplantation, predicts mortality from liver disease.  Patients with hepatocellular 
carcinoma (HCC) risk disease progression not reflected in their MELD score. 
Exception scores prioritize HCC patients higher than their MELD scores, but 
advantage them over non-HCC patients.  To address this, a delay of six months 
for using exception scores has been implemented, and alternative HCC-specific 
scores have been developed.  Using multistate models, this study projects 
waitlist dropout and transplant probabilities under the delay and under two 
alternative scores.  The delay improves equity between HCC and non-HCC 
patients for the first six months waitlist time, but still advantages HCC patients 
after six months. Both alternative scores would improve this inequity but increase 
dropout for some HCC risk groups and decrease HCC transplant probabilities 
below non-HCC probabilities.  Further calibration of these scores is 
recommended prior to considering them for implementation. 
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CHAPTER 1 
INTRODUCTION 
The Model for End-Stage Liver Disease (MELD) score, which predicts 
three-month mortality from liver disease, has been used to allocate liver 
transplants to patients with the most need or urgency for transplant under 
policies of the Organ Procurement and Transplantation Network (OPTN). The 
organ transplant system is managed in the Unites States through these policies 
by the United Network for Organ Sharing (UNOS) under contract with the federal 
government.  The MELD score was originally used to predict three-month 
mortality for patients receiving TIPS (Transjugular Intrahepatic Portosystemic 
Shunt) procedures1, and subsequently generalized to predict three-month 
mortality risk in patients with end-stage liver disease2. 
The MELD score is based on the biochemical values of bilirubin, 
international normalized ratio (INR) and creatinine.  It is defined by: 
0.957*ln(creatinine) + 0.378*ln(bilirubin) + 1.12*ln(INR) + 0.643 
where creatinine and bilirubin are in milligrams per deciliter (mg/dL).  The result 
of this calculation is rounded to the tenth decimal place and then multiplied by 10.  
The minimum of this score is 6, and the maximum is 40.  Laboratory values less 
than 1 are set to 1 for the calculation, and creatinine is set to 4 for candidates 
with creatinine greater than 4 or those who received two or more dialysis 
treatments or 24 hours of continuous veno-venous hemodialysis within the prior 
week3.
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Liver transplant has been shown to be an appropriate treatment for 
patients with hepatocellular carcinoma whose tumor characteristics meet certain 
criteria for size and number.  These criteria, a single tumor 5 cm or less in 
diameter or up to 3 tumors 3 cm or less in diameter, have been referred to as the 
Milan criteria4.  Patients with hepatocellular carcinoma (HCC) often have higher 
mortality risk than their calculated MELD scores would indicate due to tumor 
progression rather than liver disease5, and also risk of dropout from the waiting 
list due to HCC progression beyond criteria. In attempt to account for this, HCC 
patients have been allocated exception MELD scores per OPTN policies which 
are generally greater than their calculated MELD score. However, risk of tumor 
progression beyond the Milan criteria within three months was later found to be 
overestimated by these exception points 6, such that HCC patients have had 
higher transplant rates and lower waitlist dropout rates than non-HCC 
candidates.  Thus, policies have been revised several times – for example, 
candidates with single tumors less than 2 cm in size were originally granted 
exception points but currently are not.  Under recent policy, candidates with HCC 
who met criteria according to OPTN policies received an initial exception MELD 
score equivalent to a 15 percent risk of 3-month mortality7.  Criteria in the OPTN 
policies include stage T2 lesions, which may be one lesion greater than or equal 
to 2 cm and less than or equal to 5 cm in size, or two or three lesions greater 
than or equal to 1 cm and less than or equal to 3 cm in size.  Additional exception 
points equivalent to a 10% increase in mortality risk were given every three 
months thereafter, until the patient received a transplant or became unsuitable 
for transplant based on their HCC progression 7.   
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Under this system, despite previous modifications, patients with HCC 
continued to have an advantage for access to transplantation when compared to 
patients without HCC 5,8.  Because previous policies provided advantages to 
HCC patients compared to non-HCC patients, with increased transplant rates 
and lower dropout rates9, OPTN/UNOS recently implemented a six-month delay 
before granting exception points3.  Simulation modeling previously suggested 
that this delay would help decrease disparity between HCC and non-HCC 
candidates 10.  With the six-month delay, HCC patients will be listed at their 
laboratory MELD score until the second three month extension.  At that time they 
will receive an exception MELD score equivalent to a 35% risk of 3-month 
mortality (score of 28) and then continue with the scheduled exception point 
progression every three months until they receive transplantation or become 
unsuitable based on HCC progression. The exception point progression will be 
capped at 34 points 3.   
In addition to the six-month delay, investigators have proposed alternative 
scoring models for HCC patients in attempt to address the disparity in access to 
transplantation between HCC and non-HCC patients 6,11-15.  These scores were 
intended to more accurately reflect dropout risk for HCC patients based on HCC 
and patient characteristics in addition to the laboratory MELD.  Several of these 
scores were summarized in a previous publication 16 and those models as well as 
another model15 that was developed more recently will be briefly described here. 
Review of Equivalent MELD Scores 
One of the alternative HCC transplant prioritization scores, developed by 
Freeman et al, estimates 90-day dropout probability for HCC patients using an 
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equation based on calculated MELD score at listing, maximum tumor size, and 
alpha-fetoprotein (AFP) 6, a laboratory test used by clinicians in screening for and 
monitoring HCC17.  The dropout probability from the equation can then be 
matched to the non-HCC MELD score with that same dropout probability.  They 
developed this equation by examining multiple covariates using Cox regression 
models with the endpoint of time to dropout. Their data included 11431 patients, 
2052 of whom received exceptions due to HCC, on the waiting list between 
4/30/2003 and 12/31/04. They found that MELD at listing, maximum tumor size, 
AFP and age at listing were associated with an increased relative risk of waitlist 
removal (dropout), while ablation, diagnostic imaging modality (magnetic 
resonance imaging or ultrasound vs computerized tomography), number of 
tumors, race, gender and blood type did not have significant relative risks for 
removal.  They purposefully used only nondiscriminatory variables in the 
equation, so age was excluded.  They assessed the accuracy of their equation 
with newer waiting list data from 1/1/2005 to 4/20/2005 that included 624 HCC 
candidates and found that the concordance of their model was 0.781 (95% CI 
0.688, 0.853).  However, MELD alone was equally predictive of dropout with 
concordance of 0.796 (95% CI 0.657, 0.897).  Additionally, this model was 
validated in a separate study in 2008 on 390 HCC transplant candidates who 
received locoregional therapy. This study found concordance of 0.81 (0.685, 
0935) at three months and 0.8 (0.732, 0.868) at six months for this model’s 
accuracy in predicting tumor progression.  For this group of patients, the model 
was more predictive than MELD alone, which had concordance of 0.574 (0.420, 
0.728) at three months and 0.538 (0.413, 0.663) at six months 18.  The authors of 
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the validation study noted that the patients undergoing locoregional therapy had 
low baseline MELD scores that could be a reason for the contrast with the 
original study, which found that MELD was equally predictive of dropout.  
Advantages of this score include that it was externally validated and it also 
identified risk factors for HCC waitlist dropout.  Disadvantages are that it 
estimates dropout probability rather than an actual score, so may be difficult to 
implement in practice.  Also, although it was validated, it was not found to be 
better than MELD alone in predicting dropout when validated on a larger, broader 
group of patients. 
Another score that has been developed is that by Piscaglia et al.  This 
score adds points to the lab MELD for waitlist time in months and a “stage score” 
that incorporates tumor size and consideration for downstaging11.   The stage 
score included 5 points for a single nodule up to 3 cm in size, 8 points for larger 
tumors or multifocal tumors within the Milan criteria, or 12 points for downstaging 
protocol.  The authors stated that the number of points chosen were arbitrary, but 
did increase with increasing disease stage to reflect higher risk of dropout. The 
downstaging protocol in this study allowed patients with HCC previously beyond 
Milan criteria who underwent surgery or locoregional treatment to be listed for 
transplant if the tumor size was reduced to within Milan criteria and their AFP 
level did not exceed 400 nanograms per milliliter (ng/mL) during listing.  During 
the time of the study, the Bologna Transplantation Center in Italy adopted a 
MELD-based prioritization policy (UNOS also began using the MELD in 2002 
along with exception points for HCC patients), but used its own allocation policy, 
which was the score described above, for patients with HCC.  The patients in the 
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study included 301 HCC and non-HCC patients listed for transplant at the 
Bologna Transplantation Center from 3/1/2001 to 2/28/2004, including 163 
patients listed before the policy implementation and 138 listed after.  They 
compared dropout and transplant rates between HCC and non-HCC patients 
before implementing this policy and after it had been in place for one year.  They 
did not find a difference in dropout between the two time periods, but HCC 
patients had a significantly higher cumulative probability of transplant, assessed 
using Kaplan-Meier curves, compared to non-HCC patients after implementing 
the new score.  This transplant probability was also significantly higher compared 
to HCC probabilities before implementing their new score, and they did not find 
this difference for non-HCC patients.  There was concern that the transplant 
rates for HCC were excessively greater than those for non-HCC patients when 
the policy was first implemented.  However, the authors stated that when their 
policy was first implemented many HCC patients initially received priority due to 
their long waiting time, but after these initial patients underwent transplantation 
the rates became more equal between HCC and non-HCC patients.  They also 
pointed out that non-HCC dropout rates did not significantly increase; however, 
the proportion of non-HCC patients still waiting for transplant at the end of the 
study period did increase.  Based on this, the policy at that center was updated to 
provide fewer points: 3 points for a single tumor up to 3 cm with 0.5 points per 
month waiting time and 6 points for larger tumors, multiple tumors or 
downstaging protocol with 1 point per month waiting time.  Results of this 
updated score were not included in the study.  Advantages of this score include 
that it does consider HCC characteristics in addition to MELD.  Another 
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advantage, in theory, is that it was updated based on results, reflecting the idea 
that patient and center characteristics can change over time, though results of 
the update are not known.  Other authors have stated that allocating increased 
points for downstaging is controversial as these patients may have decreased 
dropout risk16; also a waiting period before transplant may be recommended19.  
While downstaging protocols are used in some regions in the United States19,20, 
automatic exception points for downstaged tumors are generally not given3,20, so 
implementing a score that gives increased points for downstaging in the US may 
be difficult.  
Another equivalent MELD score, developed by Vitale et al14, was derived 
using transplant benefit rather than dropout risk as an endpoint to equate with 
that of non-HCC patients. This is in contrast to several of the other scores 
reviewed here which equate to non-HCC using dropout risk.  It also includes a 
separate utility score intended to avoid poor post-transplant outcomes.  The 
authors state that using 3-month dropout risk as an endpoint for both HCC and 
non-HCC patients may be problematic because dropout for non-HCC patients is 
usually due to death, whereas dropout for HCC patients is usually due to tumor 
progression.  To derive their score, the investigators studied covariates using 
competing risk models for analyzing waitlist outcomes, to allow for the outcomes 
of transplant, death or still waiting, and Cox proportional hazard regression 
models for analyzing transplant outcomes.  They studied 2697 patients who were 
placed on the transplant waiting list and 1702 who were undergoing liver 
transplant during 2004-2009 in the North Italy Transplant Program area. The final 
covariates used in the score were laboratory MELD and AFP.  The paper notes 
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that AFP was associated with death on the waitlist for HCC patients, but had a 
more significant impact on post-transplant survival.  Monthly death probabilities 
were obtained from the competing risk and Cox models, and then used to 
simulate 1000 outcomes (life expectancy in months based on the covariates) for 
both HCC and non-HCC groups.  Then a regression model was used to estimate 
the five-year transplant benefit based on MELD for non-HCC patients and MELD 
and AFP for HCC patients, and these were equated between the two groups to 
obtain an equivalent MELD score.  Thus, the HCC transplant survival benefit for 
a given equivalent MELD score would be equal to that of non-HCC patients with 
the same numerical value for MELD.  They also developed a utility score that, 
expressed as a linear relationship between log10AFP and MELD, calculates the 
maximum MELD a patient may have with any given AFP value (or vice versa) to 
prevent unacceptable post-transplant outcomes, which were defined as less than 
50% survival at five years.  Another difference between this score and others 
reviewed here is that the term for AFP is negative (so a patient will receive fewer 
points for a higher AFP), which follows from their findings that AFP had a more 
significant impact on post-transplant survival and their use of survival benefit as 
the point to equate with non-HCC MELD scores.  An advantage of this score is 
that it does consider both dropout and post-transplant survival.  A disadvantage 
may be that AFP is the only HCC-specific characteristic included in the model, 
where other investigators have found that additional HCC-related characteristics 
such as tumor size can influence dropout risk5,6.  The authors state that the score 
needs external validation and further refinement.   
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Toso et al developed an HCC scoring model called the dropout equivalent 
MELD in 2012 that included age, laboratory MELD, tumor size, ln(AFP), number 
of tumors, diagnosis (additional causes of liver disease including alcohol, 
hepatitis C virus, hepatitis B virus, hemochromatosis, non-alcoholic 
steatohepatitis and “other”) in the prediction of three-month dropout probability12.  
The coefficients were positive for all the HCC-related covariates in the score as 
well as for age.  In deriving this model, the investigators used OPTN data from 
January 2004 to December 2009 including 5498 HCC patients and 43528 non-
HCC patients.  They restricted age to ≥45 years. Other variables explored 
included total tumor volume.  They used multistate modeling, competing risks 
analysis and linear regression to identify covariates associated with three-month 
dropout probability and to model that probability as a function of them. They 
derived an equation estimating a logit transformation of dropout probability as a 
function of the covariates for each group, HCC and non-HCC, and then set the 
HCC and non-HCC equations equal to each other to obtain the dropout 
equivalent MELD.  The paper notes that all patients with HCC are given the 
same number of exception points at each time point under the current policy.  
Though most are given a higher score than their dropout probability warrants, 
some HCC patients would be underserved by receiving a lower score than their 
dropout probability would indicate based on their HCC characteristics.  
Advantages of this score include that it incorporates several HCC-related 
covariates, which were previously established as risk factors for dropout, and is 
on the same scale as the laboratory MELD.  Disadvantages include the potential 
ethical concern of including age in the model as well as possible worse post-
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transplant outcomes for older patients, and also the potential of higher scoring of 
patients with aggressive tumors who may have higher risk of HCC recurrence 
post-transplant.  The paper notes that prospective assessment and external 
validation of the model could address this along with a minimum 3-month wait 
before transplantation if needed, to exclude those with high risk of post-transplant 
recurrence.  The authors also noted the need for ongoing assessment and 
updating of such a model; for example, adjustment for newly identified risk 
factors for dropout or changes in other HCC treatments. 
In 2014, Toso et al developed a new equivalent MELD score that uses 
laboratory MELD, number of tumors, AFP, and tumor size 13. This model was 
developed using a training set of 49026 patients from the United States, listed 
between 1/1/2004 and 12/31/2009, and validated on two datasets, one with 
20475 United States patients (listed 1/1/2009 to 12/31/2011) and the other with 
1781 United Kingdom patients (listed 7/1/2008 to 9/30/2011).  The coefficients for 
all the covariates in this equivalent score are positive.  The score uses discrete 
cutoff points, noted by the authors to be clinically relevant, for all the covariates 
except laboratory MELD.  This is discussed further in Chapter 3.  In contrast, 
their previous score used continuous values for most covariates. For this model, 
the investigators decided not to use age and type of liver disease since these 
factors are not used when prioritizing non-HCC patients.  Similarly to the model 
they developed in 2012 described earlier, this model was based on three-month 
dropout probability, which was modeled using the covariates listed above and 
then equated to the three-month dropout probability of non-HCC patients to 
obtain an equivalent HCC MELD score.  They termed this score the “new dropout 
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equivalent MELD (deMELD)”.  Using the validation data sets, they validated the 
resulting score as well as the exception MELD score, laboratory MELD, and a 
variation of their score which takes the maximum of the calculated new deMELD 
and the laboratory MELD (termed “mixed new deMELD”).  The concordance 
indices for the mixed new deMELD were 0.67 (95%CI 0.622, 0.714) in the US 
validation set and 0.652 (95%CI 0.553, 0.745) in the UK validation set, compared 
to 0.566(0.532, 0.597) and 0.527(0.483, 0.594) respectively for the exception 
MELD and 0.663(0.616, 0.707), 0.657(0.56, 0.75) respectively for the laboratory 
MELD.  The authors recommended that the score be updated at least every 3 
months during listing, and this would capture improvements due to other 
therapies such as ablation (e.g. a smaller tumor size after treatment would result 
in a lower deMELD score).  Again, they noted that the score could lead to 
transplantation of patients with more aggressive HCC that risk post-transplant 
recurrence, and suggested considering a 3-6 month waiting time to help control 
this risk.  They also discussed the potential of building a model based on 
transplant benefit rather than or in addition to dropout risk. 
The MELDEQ, derived by Marvin et al in 201515, includes laboratory 
MELD, ln(AFP), number of tumors, maximum tumor size, and a constant that is 
increased after six months on the waiting list.  The authors derived this score 
using OPTN data from 1/22/2005 to 9/30/2009, including 7289 HCC patients and 
34310 non-HCC patients.  They examined previously established covariates 
using Cox regression including laboratory MELD, ln(AFP), number of tumors, and 
tumor size; all were significant predictors of dropout.  The authors then equated 
the dropout hazard based on these covariates to that of non-HCC patients based 
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on MELD alone to derive an equivalent MELD score.  An approximation of the 
difference in log baseline hazard rates for dropout between HCC patients and 
non-HCC was made to determine a constant for less than 6 months after listing 
and another for waitlist time of 6 months or greater. Also, if the laboratory MELD 
was greater than the calculated MELDEQ, the MELDEQ was taken to be the 
laboratory MELD.  In addition, projections were made using multistate modeling 
to determine what transplant and dropout probabilities would be for HCC patients 
if the MELDEQ were implemented.  This projection method is the same as that 
described in the study in Chapter 3 of this thesis, and is discussed there in detail.  
The authors of the original MELDEQ study found a concordance index of 0.741 
for waitlist dropout.  Advantages to the MELDEQ include that it uses HCC 
characteristics as well as laboratory MELD and is on the same scale as the 
laboratory MELD.  Also, projections for its use, stratified by ranges of the MELD 
and MELDEQ scores, were made in its original publication.  With these 
projections, the authors noted good alignment with the non-HCC groups in 
projected transplant probabilities, such that HCC patients and non-HCC patients 
with similar dropout risk based on MELDEQ and MELD strata also had similar 
projected transplant probabilities.  A disadvantage, based on their projections, is 
that HCC projected dropout probabilities did not match the corresponding actual 
non-HCC probabilities as well as ideal for most strata; they were projected to 
decrease below non-HCC probabilities for higher risk strata. The investigators 
also noted that patients at higher risk for dropout as determined by their higher 
MELDEQ score also had worse post-transplant survival, so a potential problem 
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with this score could be increased transplantation in patients who may have 
poorer outcomes. 
In summary, all of the proposed scores reviewed here have potential to 
improve equity between transplant and dropout probabilities between HCC and 
non-HCC patients, since they take HCC characteristics into account, and several 
of them took calculated HCC dropout risk into account.  In contrast, the 
scheduled exception point progression that has been in place, and will still be in 
place after six months on the waiting list, assigns the same priority scores to all 
HCC patients regardless of their actual risk of dropout.  Of the equivalent scores 
described here, the MELDEQ and mixed new deMELD were derived most 
similarly, use similar covariates, and both are on the same scale as the MELD 
itself.    
The primary aims of this thesis were to project outcomes for both HCC 
and non-HCC patients under the recently implemented six-month delay 
compared with under the MELDEQ, as well as evaluate alternative MELD scores 
for use by HCC patients.  Evaluation of the six-month delay compared to the 
MELDEQ will be discussed in Chapter 2.  Since the MELDEQ and the mixed new 
deMELD are the most similar as described above, they were selected for 
comparison with each other in terms of projected transplant and dropout 
probabilities.  This comparison will be presented in Chapter 3.  Concluding 
remarks and future research are given in Chapter 4. 
Per the University of Louisville Human Subjects Protection Program 
Guide-006, the OPTN data used here are considered public and do not meet the 
definition of “human subject”, so IRB review and approval was not needed.  The 
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data reported here have been supplied by UNOS as the contractor for OPTN. 
The interpretation and reporting of these data are the responsibility of the 
author(s) and in no way should be seen as an official policy of or interpretation by 
the OPTN or the US Government.
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CHAPTER 2 
  
SIX-MONTH DELAY AND MELDEQ COMPARISON 
 
 
As discussed in Chapter 1, under recent OPTN policies where exception 
points were given at listing and then progressed every three months for liver 
transplant candidates with HCC, patients with these exceptions have had higher 
transplant rates and lower dropout rates compared to patients without HCC 5,8.  
To address this, a delay of six months before granting exception points to HCC 
patients has recently been implemented.  A secondary aim of this delay was to 
avoid transplanting HCC patients with aggressive tumors who may have a high 
recurrence risk post-transplant.  Under the delay, candidates will be listed at their 
laboratory MELD scores until the second three month extension, at which time 
they will be assigned 28 points and continue with the scheduled progression of 
exception points.  These exception points will be capped at 34 3.  
Other methods for addressing this disparity between HCC and non-HCC 
patients have been proposed, including equivalent MELD scores for HCC 
patients 6,11-15. These scores were meant to reflect mortality risk for HCC patients 
more accurately than scheduled progression of exception points.  These are 
described in Chapter 1, including the MELDEQ, which again was derived by 
determining dropout hazard rates based on established HCC characteristics as 
well as laboratory MELD and then equating this hazard to that of non-HCC  
patients to find the corresponding equivalent MELD score.  Incidentally, as noted 
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in Chapter 1, the MELDEQ also included a waitlist time factor derived as part of 
the scoring system which increased an HCC patient’s score after 6 months on 
the waiting list15.  As it is on the same scale as the laboratory MELD score for 
non-HCC patients, it could be used comparably.   
The main objective of this study was to compare the projected effect of the 
six-month delay to prioritization using MELDEQ scores on HCC and non-HCC 
dropout and transplant probabilities.  These projections for HCC patients were 
studied for the MELDEQ in its original publication15, and projections for transplant 
rates and mortality under the delay were previously studied by Heimbach et al 
using simulation methods10.  However, the current study compares outcomes 
under both approaches and utilizes more recent UNOS data.  Further, while the 
previous MELDEQ study only evaluated projected effects on HCC patients, the 
current study includes projections for non-HCC patients as well.  And though the 
earlier study by Heimbach et al demonstrated improved equity between HCC and 
non-HCC patients using the six-month delay, the effects of the delay on patients 
in various dropout strata were not specifically examined.  Using UNOS data and 
multistate modeling, projected waitlist dropout and transplant probabilities were 
evaluated for both HCC and non-HCC patients in varying risk strata under the 
six-month delay and the MELDEQ scoring system.  
 
METHODS 
Data 
Data were obtained on all patients who were added to the UNOS liver 
transplant waitlist on or after 10/01/2009, based on OPTN data as of 06/30/14, 
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and who were at least 18 years old at time of initial listing.  Patients with 
exceptions other than HCC were excluded, and the non-HCC dataset restricted 
to patients with no exceptions.  Patients listed as status 1A or 1B and HCC 
patients who were missing HCC-related covariate data were also excluded.  
 
Outcomes and Covariates 
The main outcomes studied included actual and projected dropout and 
transplant probabilities for HCC and non-HCC patients based on the recent 
practice of scheduled progression of exception points, the six-month delay, and 
prioritization using MELDEQ scores. The covariates used in the MELDEQ model 
were the natural log of AFP (ln(AFP)), laboratory MELD, maximum tumor size, 
and number of tumors.  Dropout was defined as removal from the waiting list due 
to death, determined medically unsuitable, or too sick for transplant.  Transplant 
was defined as having received transplant for any reason. Those who remained 
on the waiting list or were removed due to improvement were considered 
censored. 
Statistical Methods 
 The MELDEQ was calculated for all HCC patients at each follow-up time 
using the following equation: 
 MELDEQ =  max(lab MELD, 1.143*MELD + 1.324*ln(AFP)  
+ 1.438*Number of Tumors + 1.194*Max Tumor Size + c(t) ), 
where c(t) = -2/0.146 for t<6 months  
and c(t)= -1/0.146 for t≥6 months 
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Observations were categorized into ranges based on their MELDEQ and 
lab MELD scores. These ranges included <12, 12-15, 16-21, 22-27, and 28-40.  
Scores of 22 and above were categorized based on the previous exception 
points granted at three-month intervals and then combined due to sparse data in 
the higher risk groups. 
These categories were used as the transient states in a nonparametric 
multistate model for dropout and transplant probabilities, using the R package 
msSurv 21.  Figure 1 displays a schematic diagram of the multistate model used 
for this portion of the study.  In a multistate model, patients can transition 
between the transient states at any time but cannot transition out of the terminal 
states.  Briefly, our multistate model consists of five transient states (the MELD / 
MELDEQ risk categories, labeled states 1-5) and two terminal states of waitlist 
dropout (state 6) and transplantation (state 7).  Let the number of patients in 
state 𝑖𝑖 at time t be 𝑌𝑌𝑖𝑖(𝑡𝑡).  These individuals are the number ‘at risk’ of making a 
transition out of state 𝑖𝑖 at that time.  The number of individuals making a 
transition from state 𝑖𝑖 to state 𝑗𝑗 at time t is denoted 𝑑𝑑𝑁𝑁𝑖𝑖𝑖𝑖(𝑡𝑡).  Then, the non-
parametric estimate of the transition hazard from state 𝑖𝑖 to state 𝑗𝑗 at time t is 
𝑑𝑑?̂?𝐴𝑖𝑖𝑖𝑖(𝑡𝑡) =  𝑑𝑑𝑁𝑁𝑖𝑖𝑖𝑖(𝑡𝑡) 𝑌𝑌𝑖𝑖(𝑡𝑡)⁄ .  These rates give the instantaneous risk of transition 
from state 𝑖𝑖 to state 𝑗𝑗 at that time.  These transition hazards are combined into 
the state transition intensity matrix 𝑑𝑑A�(𝑡𝑡) (a 7 x 7 matrix in this case), with the off-
diagonal elements given by the 𝑑𝑑?̂?𝐴𝑖𝑖𝑖𝑖(𝑡𝑡) terms and the diagonal elements equal to 
𝑑𝑑?̂?𝐴𝑖𝑖𝑖𝑖(𝑡𝑡) = −  ∑ 𝑑𝑑?̂?𝐴𝑖𝑖𝑖𝑖(𝑡𝑡)𝑖𝑖≠𝑖𝑖 .  The state transition intensity matrices are then used to 
estimate the state transition probability matrix P(𝑠𝑠, 𝑡𝑡), where each element in the 
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matrix 𝑃𝑃𝑖𝑖𝑖𝑖(𝑠𝑠, 𝑡𝑡) gives the probability of making a transition starting from state 𝑖𝑖 at 
time 𝑠𝑠 to state 𝑗𝑗 at time t. The elements of P(𝑠𝑠, 𝑡𝑡) are estimated by the Aalen- 
Johansen estimator22 P�(𝑠𝑠, 𝑡𝑡) =  ∏ �I +  𝑑𝑑A�(𝑢𝑢)�𝑢𝑢 ∈(𝑠𝑠,𝑡𝑡] , where 𝑢𝑢 indicates the event 
times and I denotes the identity matrix (in this case a 7 x 7 matrix).  The 
multistate model was used to calculate probabilities for transplant and waitlist 
dropout (terminal states) for each risk category (transient states). The model 
accounts for transitioning between these states prior to dropout or transplant, as 
well as transitioning directly to the terminal states. 
Dropout and transplant probabilities were modeled for HCC patients. One 
model was fitted for HCC patients stratified by laboratory MELD ranges for 
evaluation of the six-month delay and another with stratification using MELDEQ.  
A similar model was constructed for non-HCC patients.  Actual dropout and 
transplant probabilities were obtained from these models.  
To address the possible concern of early transplant of high-risk HCC 
patients who may have worse post-transplant outcomes, we compared post-
transplant survival between high-risk HCC patients (MELDEQ ≥28) transplanted 
within six months from listing and those transplanted after six months.  Kaplan-
Meier survival estimates and the log-rank test were used for this comparison. 
All data analysis and statistical calculations were performed using SAS 
(Version 9.4, Cary, NC) and R for Windows (Version 3.2.2). 
Projected Outcomes 
The projection estimates assume that HCC and non-HCC patients with the 
same MELD / equivalent MELD strata are transplanted at the same rate.  This is 
similar to the projection method described in the original MELDEQ paper15, 
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however here we modify the approach to account for the potential impact on non-
HCC patients as well.  This is done by assuming that the total number of 
available organs remains fixed, and organs are redistributed across strata 
according to non-HCC rates.  The technical details for the projection method are 
given below.   
Projected transplant hazard rates were obtained based on current non-
HCC transplant rates for each MELD / MELDEQ stratum 𝑖𝑖, 𝑖𝑖 = 1, … , 5, in the 
following manner (recall that the strata are defined as MELD / MELDEQ score 
ranges of <12, 12-15, 16-21, 22-27, and 28-40).  Let 𝑑𝑑𝑁𝑁𝑖𝑖7HCC(𝑡𝑡) be the total 
number of transplants to HCC patients in stratum 𝑖𝑖 at time t (here t = time since 
listing in our multi-state model) and let 𝑑𝑑𝑁𝑁𝑖𝑖7nHCC(𝑡𝑡) be analogously defined for 
non-HCC patients (recall that state 7 is the transplantation state in our model, 
see Figure 1).  For non-HCC patients being transplanted at time t, the 
conditional probability that the organ goes to the 𝑖𝑖th strata is 
𝑝𝑝𝑖𝑖(𝑡𝑡) =  𝑑𝑑𝑁𝑁𝑖𝑖7nHCC(𝑡𝑡) ∑ 𝑑𝑑𝑁𝑁𝑘𝑘7nHCC(𝑡𝑡)5𝑘𝑘=1� .  In the projections, these conditional 
probabilities for non-HCC patients are used to determine the probability that a 
transplanted organ at time t goes to the 𝑖𝑖th strata.  Let the total number of organs 
(combined HCC and non-HCC) being transplanted at time t be 𝑑𝑑𝑁𝑁∙7(𝑡𝑡) = ∑ � 𝑑𝑑𝑁𝑁𝑘𝑘7nHCC(𝑡𝑡) +   𝑑𝑑𝑁𝑁𝑘𝑘7HCC(𝑡𝑡)�5𝑘𝑘=1 .  Then the redistributed number of organs going 
to each strata (HCC and non-HCC combined) at time t are defined as 𝑑𝑑𝑁𝑁�𝑖𝑖7(𝑡𝑡) = 𝑑𝑑𝑁𝑁∙7(𝑡𝑡)𝑝𝑝𝑖𝑖(𝑡𝑡).  The fractions of these going to HCC and non-HCC patients are 
determined by the relative number at risk in each group at that time.  That is, the 
projected number of organs going to HCC patients in stratum 𝑖𝑖 at time t is 
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𝑑𝑑𝑁𝑁�𝑖𝑖7
HCC(𝑡𝑡) =  � 𝑌𝑌𝑖𝑖HCC(𝑡𝑡)
𝑌𝑌𝑖𝑖
HCC(𝑡𝑡)+ 𝑌𝑌𝑖𝑖nHCC(𝑡𝑡)� 𝑑𝑑𝑁𝑁�𝑖𝑖7(𝑡𝑡), where 𝑌𝑌𝑖𝑖HCC(𝑡𝑡) is the number of HCC 
patients in stratum 𝑖𝑖 just prior to time t and 𝑌𝑌𝑖𝑖nHCC(𝑡𝑡) is analogously defined for 
non-HCC patients.  Similarly, for non-HCC patients the projected number would 
be 𝑑𝑑𝑁𝑁�𝑖𝑖7nHCC(𝑡𝑡) =  � 𝑌𝑌𝑖𝑖nHCC(𝑡𝑡)𝑌𝑌𝑖𝑖HCC(𝑡𝑡)+ 𝑌𝑌𝑖𝑖nHCC(𝑡𝑡)� 𝑑𝑑𝑁𝑁�𝑖𝑖7(𝑡𝑡).   
Once the projected number of transplanted organs are calculated for both 
HCC and non-HCC patients for every stratum 𝑖𝑖 and time t, projected transplant 
rates can be calculated as 𝑑𝑑?̃?𝐴𝑖𝑖7HCC(𝑡𝑡) =  𝑑𝑑𝑁𝑁�𝑖𝑖7HCC(𝑡𝑡) 𝑌𝑌𝑖𝑖HCC(𝑡𝑡)�  and 𝑑𝑑?̃?𝐴𝑖𝑖7nHCC(𝑡𝑡) = 𝑑𝑑𝑁𝑁�𝑖𝑖7nHCC(𝑡𝑡) 𝑌𝑌𝑖𝑖nHCC(𝑡𝑡)� .  These transplant rates are substituted into the estimated 
state transition intensity matrix 𝑑𝑑A�(𝑡𝑡) defined previously.  Denote these matrices 
with the substituted projected transplant rates for HCC and non-HCC patients as 
𝑑𝑑𝑨𝑨�HCC(𝑡𝑡) and 𝑑𝑑𝑨𝑨�nHCC(𝑡𝑡), respectively.  Diagonal elements of I + 𝑑𝑑𝑨𝑨�(𝑡𝑡) are 
adjusted accordingly so that each row sums to one.  Then the projected 
transplant and dropout probabilities can be calculated using the Aalen-Johansen 
estimator with these newly defined transition intensity matrices as 𝑷𝑷�HCC(𝑠𝑠, 𝑡𝑡) = ∏ �I +  𝑑𝑑𝑨𝑨�HCC(𝑢𝑢)�𝑢𝑢 ∈(𝑠𝑠,𝑡𝑡]  and 𝑷𝑷�nHCC(𝑠𝑠, 𝑡𝑡) =  ∏ �I +  𝑑𝑑𝑨𝑨�nHCC(𝑢𝑢)�𝑢𝑢 ∈(𝑠𝑠,𝑡𝑡] .       
The projected transplant hazards were calculated as above for both the 
six-month delay model and the MELDEQ model.  For projections under the six-
month delay, use of the actual transplant hazards in the Aalen-Johansen 
estimator were resumed after six months to reflect reverting to scheduled 
exception point progression.  For projections under the MELDEQ, the probabilities 
were calculated using projected transplant hazards through 18 months. 
To project outcomes for patients under the MELDEQ given a patient is still  
22 
 
on the list after 6 months, separate calculations were made for 6-18 months from 
listing.  Calculations were made in an analogous fashion using the non-HCC 
multistate model, the MELDEQ HCC multistate model, and projected transplant 
hazards as described in the previous paragraphs. However, transition times 
starting at six months from listing were used. 
Overall projected and actual dropout and transplant probabilities at six, 12 
and 18 months since time of listing were calculated using the multistate models 
for the six-month delay, the MELDEQ and the prioritization scheme in place 
during the time of the study.  The variances of these estimates for actual 
probabilities were obtained using the bootstrap option in the R package 
msSurv21, with 200 iterations, and used to construct normal 95% confidence 
intervals. For projected overall probabilities, 500 bootstrap iterations of the 
projected estimates were performed and checked graphically for normality. Then 
their standard deviations were used to construct normal 95% confidence 
intervals.   
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Figure 1: Schematic Diagram of Multistate Model.  Transient states consisting 
of MELD or MELDEQ ranges are represented by circles, while the terminal states 
of dropout and transplant are represented by rectangles. Transitions are possible 
between any of the transient states (light lines), and from any transient state to 
the terminal states (bold lines). Transitions to the dropout / transplant states are 
of primary interest.
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RESULTS 
A total of 7,931 patients were listed with HCC exceptions and 34,868 
patients with standard MELD scores during the time frame between 10/1/2009 
and 6/30/2014.  Three HCC patients were missing HCC-related covariate data, 
leaving 7,928 for analysis. Table 1 shows the numbers and percentages of HCC 
and non-HCC patients who were censored, dropped out, received transplant, or 
improved as of last follow-up. Compared to non-HCC, HCC patients had a higher 
percentage of transplantation (71% vs. 39.9%) and a lower percentage of 
dropout (5.7% vs. 10.6%).   
 
 
 
Outcome 
HCC 
Count (percent) 
Non-HCC 
Count (percent) 
Censored 1837 (23.2%) 16633 (47.7%) 
Dropout 452 (5.7%) 3700 (10.6%) 
Transplanted 5629 (71%) 13895 (39.9%) 
Improved 10 (0.1%) 640 (1.8%) 
Total 7928 34868 
 
Table 1: Outcomes at last follow up for HCC and non-HCC patients. Numbers in 
each cell are the count and percentage of patients out of 7928 total HCC patients 
and 34868 non-HCC patients. 
 
Figure 2 displays actual and projected dropout and transplant probabilities 
for patients stratified by their laboratory MELD ranges during 0-18 months from 
listing.  As expected, the transplant probabilities under recent practice are similar 
for HCC patients regardless of MELD score range (Figure 2a).  There is some 
differentiation in actual dropout probabilities for HCC patients stratified by 
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laboratory MELD, though not as clear as that for non-HCC patients (Figure 2c). 
The separation in projected transplant probabilities by dropout risk strata under 
the six-month delay is much more distinct than before, though lower than the 
corresponding non-HCC patients in the same ranges (Figure 2b) for the first six 
months.  We see an increase in projected transplant probabilities compared to 
actual for HCC patients in strata with MELD scores >21 for the first 6 months, but 
a decrease for those in lower strata (c.f. Figure 2a vs. 2b).  However, after six 
months, projected transplant probabilities rapidly increase for HCC patients to 
again exceed those for non-HCC patients (Figure 2b).  Under the delay, dropout 
probabilities for HCC patients with MELD scores <22 are projected to be slightly 
higher compared to current levels (c.f. Figure 2d vs. 2c) though patients with 
higher MELD scores are expected to have reduced dropout probabilities relative 
to current.  Projected dropout probabilities are also somewhat higher for HCC 
patients with MELD scores <22 relative to non-HCC patients, but lower for HCC 
than non-HCC for patients with MELD scores ≥22.  For non-HCC patients, 
dropout probabilities are projected to be slightly reduced for those with MELD 
>15 (c.f. Figure 2c vs. 2d). 
Projections under MELDEQ are very similar to those for the six-month 
delay for the first six months of listing, as seen by comparing Figures 2 and 3 for 
the first six months shown.  During these first six months, the MELDEQ score is 
equivalent to the laboratory MELD score for 93% of observations. Table 2 shows 
the distributions of the MELDEQ and laboratory MELD for HCC patients at listing.   
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Score Ranges 
HCC MELDEQ 
Count (percent) 
HCC Lab MELD 
Count (percent) 
6-11 4759 (60.0%) 4889 (61.7%) 
12-15 2075 (26.2%) 2017 (25.4%) 
16-21 959 (12.1%) 911 (11.5%) 
22-27 126 (1.6%) 102 (1.3%) 
28-40 9 (0.1%) 9 (0.1%) 
 
 
Table 2: Frequency distributions of the MELDEQ and laboratory MELD 
scores for HCC patients at initial listing.  Numbers in each cell are the count and 
percentage of patients out of 7928 total HCC patients. 
 
Figure 3 shows actual and projected dropout and transplant probabilities 
under the MELDEQ scoring method through 18 months from listing.  At six 
months, a slight increase in projected HCC transplant probabilities is seen under 
this scheme similarly to the six-month delay, but the increase is much less 
pronounced.  This increase would be expected as the MELDEQ assigns 6.85 
more points when a patient has been on the waiting list for at least six months.  
As with laboratory MELD, actual transplant probabilities are similar over 
time for all HCC patients regardless of risk strata as determined by the MELDEQ 
(Figure 3a).  Under the MELDEQ model, projected transplant probabilities are 
much more defined according to risk strata (Figure 3b), and thus closer to non-
HCC probabilities compared to actual transplant probabilities for most strata. In 
contrast to Figure 2b, they remain this way after six months on the waitlist.  
However, they are less than projected non-HCC probabilities in the 
corresponding strata.  Non-HCC transplant probabilities are projected to increase 
slightly for all strata under this model (c.f. Figure 3a vs. 3b), while non-HCC 
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dropout would decrease slightly for all but the lowest stratum (c.f. Figure 3c vs 
3d).  Under the MELDEQ, dropout probabilities are projected to increase for those 
with scores <22 and decrease for those with scores ≥22 (Figures 3c and 3d).  
Figure 4 shows actual and projected transplant and dropout probabilities 
for HCC patients stratified by MELDEQ scores and non-HCC by MELD scores for 
six months through 18 months after listing.  These curves reflect the probability of 
transplant or dropout for a patient given she/he is still on the waitlist at six 
months.  During this time frame, actual transplant probabilities (shown in Figure 
4a) for HCC patients exceed those for non-HCC patients except for the highest 
non-HCC risk group (MELD≥28).  Projected transplant probabilities under the 
MELDEQ match those for non-HCC patients in corresponding ranges well (Figure 
4b).  Projected dropout probabilities for HCC patients under this scheme exceed 
the levels for the corresponding non-HCC strata (Figure 4d).  Compared with 
actual dropout (Figure 4c), projected probabilities would again be reduced for 
HCC patients with MELDEQ scores ≥22 but increased for those with scores <22.  
For non-HCC patients, projected dropout probabilities are similar to actual for 
MELD <16 and reduced for MELD ≥16.  The projections on Figure 4 reflect 
dropout and transplant probabilities under the MELDEQ as if it were used 
beginning at six months waitlist time.  The results displayed in Figures 2 and 3 
are aggregated and summarized in Table 3, which gives overall dropout and 
transplant probabilities and their 95% confidence intervals under recent practice 
(“actual” on Figure 3) and projected for the six-month delay and the MELDEQ at 
6, 12 and 18 months after listing.  Under the six-month delay, overall dropout at 6 
months is projected to increase slightly for HCC patients and decrease slightly for 
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non-HCC patients compared to actual probabilities, as expected, while overall 
transplant probabilities would be reduced for HCC patients and increased for 
non-HCC patients.  As noted previously, these results are very similar for the 
MELDEQ during the first six months on the waitlist. 
At 12 months waitlist time, the overall dropout probability would increase 
somewhat for HCC patients under both the six-month delay and the MELDEQ, 
while it would decrease for non-HCC patients. This change is slightly greater 
under the MELDEQ.  Again, the opposite change would be seen for transplant 
probabilities (increase for non-HCC and decrease for HCC) under these 
schemes. This change is more pronounced under the MELDEQ.  The same trend 
is seen at 18 months waitlist time. For all of these probabilities, the point 
estimates and 95% confidence intervals are shown in Table 3. 
Table 3c shows actual and projected dropout probabilities for total HCC 
and non-HCC patients, weighted by the proportion of each group to the whole 
sample.  Both the six-month delay and the MELDEQ are projected to decrease 
total dropout probabilities compared to actual, though in neither case is the result 
statistically significant as indicated by the overlap in 95% confidence intervals 
(CIs).  While the total projected dropout is nearly identical between the MELDEQ 
and the six-month delay at the various time points, the probabilities become 
closer over time between HCC and non-HCC patients under the MELDEQ (see 
Table 3a and 3b).  At 12 months, projected dropout probabilities under the 
MELDEQ are 8.38% and 8.89% for HCC and non-HCC respectively, and at 18 
months they are 10.82% and 10.22%.  Under the six-month delay, overall 
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projected dropout for non-HCC patients is still statistically significantly higher 
than that for HCC patients at these time points (95% CIs do not overlap). 
 
 
 
   
 
 
a. HCC Patients 
Dropout Transplant 
Actual 6-Month 
Delay 
MELDEQ Actual 6-Month 
Delay 
MELDEQ 
6 
Mo 
3.68% 
3.25, 4.11 
4.58% 
4.02, 5.15 
4.54% 
3.98, 5.1 
43.33% 
42.21, 44.45 
8.18% 
7.76, 8.61 
8.54% 
8.11, 8.97 
12
Mo 
5.63% 
5.11, 6.15 
7.73% 
6.94, 8.52 
8.38% 
7.49, 9.28 
66.29% 
65.18, 67.4 
45.92% 
44.33, 47.52 
16.5% 
15.82, 17.17 
18 
Mo 
6.42% 
5.85, 6.99 
9.02% 
8.13, 9.91 
10.82% 
9.63,12.01 
80.97% 
79.92, 81.95 
70.2% 
68.53, 71.88 
21.63% 
20.73, 22.53 
 
 
 b. Non-HCC Patients 
 Dropout Transplant 
 Actual 6-Month 
Delay 
MELDEQ Actual 6-Month 
Delay 
MELDEQ 
6  
Mo 
7.71% 
7.41, 8.01 
7.01% 
6.74, 7.27 
7.01% 
6.75, 7.28 
35.95% 
35.45, 36.45 
41.19% 
40.66, 41.72 
41.14% 
40.62, 41.67 
12 
Mo 
10.15% 
9.78, 10.52 
9.1% 
8.79, 9.42 
8.89% 
8.59, 9.2 
42.74% 
42.17, 43.31 
46.84% 
46.31, 47.37 
49.77% 
49.25, 50.29 
18 
Mo 
11.9% 
11.51,12.29 
10.7% 
10.34,11.05 
10.22% 
9.89,10.56 
46.4% 
45.76, 47.04 
50.1% 
49.56, 50.65 
54.49% 
53.96, 55.02 
 
 
 c. Total (HCC and non-HCC) Dropout 
Actual 6-Month Delay MELDEQ 
6  
Mo 
6.96% 
6.64, 7.29 
6.56% 
6.24, 6.88 
6.55% 
6.24, 6.87 
12 
Mo 
9.31% 
8.92, 9.71 
8.85% 
8.45, 9.25 
8.8% 
8.39, 9.21 
18 
Mo 
10.88% 
10.46, 11.31 
10.39% 
9.93, 10.84 
10.33% 
9.84, 10.83 
 
 
Table 3: Overall dropout/transplant probabilities with 95% confidence intervals 
for HCC and non-HCC patients, actual and projected with prioritization under the 
6-month delay and MELDEQ at 6, 12, and 18 months waitlist time. 
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Figure 2: Actual and projected time to transplant and dropout for HCC and 
non-HCC patients stratified by laboratory MELD score.  Time is from 0 to 18 
months after listing.  Solid lines indicate the probability of transplant/dropout for 
HCC patients under the current scheme (a,c) and under the six-month delay in 
assigning exception points (b, d).  Dashed lines indicate the corresponding 
probability curves for non-HCC patients.  The number at risk for HCC patients at 
baseline, 6, and 12 months is given in the upper part of panel c. 
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Figure 3: Actual and projected time to dropout or transplant for HCC 
patients stratified by MELDEQ score and non-HCC patients by MELD.  Time 
is from 0-18 months after listing. The curves reflect the probability of transplant or 
dropout under the current scheme (a, c) and those projected under the MELDEQ 
scoring system (b, d).  Solid lines represent probabilities for HCC patients while 
dashed lines represent those for non-HCC patients.  The number at risk for HCC 
patients at baseline, 6, and 12 months is given in the upper part of panel c. 
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Figure 4: Actual and projected time to dropout or transplant for HCC 
patients stratified by MELDEQ score and non-HCC patients by MELD.  Time 
is from 6 months until 18 months after listing. The curves reflect the probability, 
given a patient is still on the waiting list at 6 months, of transplant or dropout 
under the current scheme (a, c) and those projected under the MELDEQ scoring 
system (b, d).  Solid lines represent probabilities for HCC patients while dashed 
lines represent those for non-HCC patients.  The number at risk for HCC patients 
at 6, 9, 12, and 15 months is given in the upper part of panel c. 
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Lastly, since part of the rationale of the six month delay was to possibly 
avoid transplanting high-risk HCC patients earlier who may have poorer 
outcomes, post-transplant survival was compared between patients classified as 
higher-risk (MELDEQ ≥28) and transplanted within six months (n=26)  vs. after six 
months (n=81) from listing.  Although post-transplant survival was somewhat 
lower for those transplanted earlier, this was not statistically significant (p=0.285). 
DISCUSSION 
In this part of the study, projections were evaluated for dropout and 
transplant probabilities under the recently implemented six-month delay for 
granting exception MELD points to HCC patients and compared to prioritization 
based on the MELDEQ.  While the six-month delay will improve equity of 
transplant probabilities between HCC and non-HCC patients for the first six 
months on the waiting list, these results show that reverting to scheduled 
exception point progression after six months will again advantage HCC patients.  
Additionally, reverting to exception points after six months still treats all HCC 
patients as having the same dropout risk regardless of tumor characteristics or 
laboratory MELD.     
Dropout was projected to increase under the delay for HCC patients with 
MELD scores <22, but projected to decrease for both HCC and non-HCC 
patients with MELD scores ≥22.  This increase in dropout for lower HCC risk 
groups is in contrast to findings in the original study describing the derivation of 
the MELDEQ 15.  In that study, it was projected that patients with MELDEQ scores 
≤15 would not be adversely affected by the six-month delay while those with  
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higher scores could be adversely affected in terms of dropout probability.  It was 
noted that the advantage to HCC patients was not universal, as dropout 
probabilities for lower risk HCC patients (MELDEQ≤15) were lower than their non-
HCC counterparts while their transplant probabilities were higher.  The opposite 
(higher dropout, lower transplant) was true for patients in higher MELDEQ ranges.  
While this appears to still be the case for transplant probabilities, dropout for 
most HCC groups in the current study appears to be lower than in the original 
MELDEQ study.  Overall HCC dropout probabilities in the current study were 
found to be 3.68% at 6 months and 5.63% at 12 months while in the earlier study 
they were 4.7% at 6 months and 7.2% at 12 months 15.  Also, since the original 
MELDEQ study modeled dropout and transplant since the time a patient first 
entered a score range and the MELDEQ assigns more points once a patient has 
been on the waitlist for six months, it is likely that some of the higher risk patients 
identified in the earlier study had already been on the list for six months or more.  
In order to make comparisons with the six-month delay, in this study we modeled 
these probabilities using time since listing.  
While dropout probabilities were projected to increase somewhat for HCC 
patients under both the six-month delay and the MELDEQ, the magnitude of this 
increase was much smaller than that of the projected decrease in HCC transplant 
probabilities. This was particularly evident under the MELDEQ.  Results from the 
paper by Heimbach et al also suggested that increased mortality rates may not 
accompany decreased transplant rates for HCC patients 10.  However, the 
reduction of HCC transplant probabilities below those of non-HCC candidates is 
still a limitation of the MELDEQ, as ideal prioritization would equalize both 
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transplant and dropout probabilities between HCC and non-HCC patients overall 
and according to dropout risk strata. 
Other investigators have looked at the balance between waiting time, 
waitlist dropout, post-transplant survival and equity of transplant rates, and found 
that increased waiting time was associated with either improved overall survival 
(while on the waiting list and post-transplant) or post-transplant survival 23-25.  The 
possible benefits and risks of increased waiting time were also discussed in a 
paper by Roayaie & Roayaie, who point out that while increased waiting time was 
associated with longer post-transplant survival, waiting too long begins to remove 
patients who would have done well post-transplant 26. While findings here include 
slightly lower post-transplant survival for HCC patients transplanted earlier 
versus later, this result was not statistically significant.  It should be noted that 
this comparison was only made for patients with MELDEQ of at least 28 at their 
last follow up prior to transplant, which was a small sample size (n=107).  
Increased waiting time was not the primary goal of the MELDEQ, though it does 
assign a higher score once a candidate has been on the list for six months. 
A limitation of this study is that the representation of organ availability 
used in the projections may not be completely realistic since projections were 
modeled using time since listing rather than calendar time. That is, the number of 
organs estimated to be available at a certain time t is based on how many 
candidates received an organ at that time t since listing.  However, this method 
still provides an estimate of the proportion of transplants going to each group and 
the projected change for HCC relative to non-HCC candidates under each 
prioritization system.  Also, evaluating three prioritization systems this way can 
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still provide a valid comparison of them, as they were all compared using the 
same projection method.  
Strengths of the study include examination of the effects of the six-month 
delay and the MELDEQ over time, including projections after six months on the 
waitlist, and study of these effects among different HCC dropout risk strata. While 
equalizing HCC and non-HCC dropout and transplant probabilities overall is the 
primary goal, part of this goal is to prioritize those patients who most urgently 
need and can benefit the most from transplantation. Studying outcomes for each 
stratum based on a score utilizing HCC characteristics can help identify those 
patients and help to further calibrate HCC-based scores. 
In conclusion, despite improvement in equity for the first six months under 
the delay, reverting to scheduled exception point progression after six months 
continues to advantage HCC patients.  Thus an HCC-specific prioritization 
method, particularly for use after six months, is still needed.  Utilizing the 
MELDEQ after six months would improve equity of transplant probabilities 
between HCC and non-HCC patients, and its use through six months yields 
results similar to those of the six-month delay.  Further, while overall projected 
dropout probabilities were nearly identical for the MELDEQ and 6-month delay, 
projected differences between HCC and non-HCC patients were smaller under 
the MELDEQ.  However, using the MELDEQ is projected to increase dropout 
beyond non-HCC probabilities for some HCC risk strata.  Therefore, further 
adjustment of the score would be needed before consideration for use in 
practice.
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CHAPTER 3 
MELDEQ AND deMELD COMPARISON 
For this study, two of the aforementioned equivalent MELD scores, the 
MELDEQ 15 and the mixed new dropout equivalent MELD 13 (referred to in this 
chapter as simply “deMELD”) were evaluated.  Recall from Chapter 1 that these 
scores were derived by determining dropout probabilities or hazards based on 
established HCC characteristics as well as laboratory MELD, and then equating 
these HCC probabilities or hazards to those of non-HCC patients to find the 
corresponding MELD score.  Both deMELD and MELDEQ scores could be used 
for HCC patients comparably to the laboratory MELD for non-HCC patients since 
they are on the same scale.  The deMELD was designed according to the 
probability of dropout from the waiting list while the MELDEQ equated dropout 
hazards. 
The primary aims of the current study were to compare the predictive 
accuracy for waitlist dropout of both scores and to evaluate possible effects of 
prioritization with these scores on waitlist dropout and transplant probabilities.  
These outcomes were studied in both original publications 13,15, but the intent 
here was to validate the scores with newer data and to compare the scores with 
each other. Secondary goals were to study how changes in HCC-related 
covariates affected both alternative MELD scores, and compare post-transplant 
survival between patients in various ranges of the scores. 
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METHODS 
The same datasets for HCC and non-HCC patients as described in 
Chapter 2 were used for this study as well.   
Outcomes and Covariates 
The main outcomes studied included actual dropout and transplant 
probabilities for HCC patients under the scheduled progression in place during 
the timeframe of the study compared to those of non-HCC patients and those 
probabilities projected under the deMELD and MELDEQ.  Also, post-transplant 
survival of patients stratified by ranges of the two alternative scores was 
evaluated.  In addition, the effect of differences in the included covariates on 
categorization by the two alternative scoring models was examined.  The 
covariates from these two models were alpha-fetoprotein (AFP) or the natural log 
of AFP, laboratory MELD, maximum tumor size, and number of tumors.  
Additionally, the MELDEQ calculation includes a constant which increases when 
waitlist time reaches six months.   
Dropout, transplant and censored were defined in the same manner as the 
study described in Chapter 2.  
Statistical Methods 
 All data analysis and statistical calculations were performed using SAS 
(Version 9.4, Cary, NC) and R (Version 3.1.1).  The MELDEQ and deMELD were 
calculated for each observation of HCC patients in the dataset using the following 
equations: 
 MELDEQ =  max(lab MELD, 1.143*MELD + 1.324*ln (AFP)  
+ 1.438*Number of Tumors + 1.194*Max Tumor Size + c(t) ), 
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where c(t) = -2/0.146 for t<6 months and c(t)= -1/0.146 for 
t≥6 months 
 
deMELD = max(lab MELD, -37.8 + 1.9*MELD  
+ 5.9 if Number of Tumors ≥2  
+ 21.2 if Max Tumor Size >1 cm + 5.9 if AFP>400)   
 
AFP values less than 1 were taken to be 1 for the purpose of calculating 
ln(AFP). The observations were then categorized into ranges based on their 
MELDEQ and deMELD. These ranges included <12, 12-15, 16-18, 19-21, 22-24, 
25-30, 31-35, and 36-40.  These categories were then used as the transient 
states in nonparametric multistate models for dropout and transplant 
probabilities, using the R package msSurv.  The multistate model is discussed in 
detail in the paper describing the msSurv package by Ferguson et al 21.  Figure 5 
depicts a diagram of the multistate model used for this study.  This is similar to 
the multistate model used in Chapter 2, but this model has eight transient states 
since eight risk strata were created as described above.  The terminal states 
again are dropout and transplant. 
Time zero was taken to be time first entering a given score range.  This 
approach was used because clinically, projections for a patient given their current 
score or risk level are of interest in addition to their risk at listing.  Also, very few 
patients were categorized in the highest risk groups at listing by either alternative 
score, as shown in Table 4. 
 
 
40 
 
 
 
 
Figure 5: Schematic Diagram of Multistate Model.  Transient states consisting 
of MELD or alternative MELD ranges are represented by ovals, while the terminal 
states of dropout and transplant are represented by rectangles. Transitions are 
possible between any of the transient states and another transient state (light 
lines), and from any transient state to the terminal states (bold lines). Transitions 
to the dropout / transplant states are of primary interest. 
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Score 
Ranges 
HCC MELDEQ deMELD 
Initial listing Last follow-up Initial Listing Last follow-up 
6-11 4759 (60.0) 4081 (51.5) 4861 (61.3) 4580 (57.8) 
12-15 2075 (26.2) 2021 (25.5) 1803 (22.7) 1814 (22.9) 
16-18 692 (8.7) 933 (11.8) 676 (8.5) 766 (9.7) 
19-21 267 (3.4) 469 (5.9) 250 (3.2) 279 (3.5) 
22-24 103 (1.3) 226 (2.9) 160 (2.0) 222 (2.8) 
25-30 29 (0.4) 155 (2.0) 134 (1.7) 173 (2.2) 
31-35 1 (0.01) 32 (0.4) 31 (0.4) 56 (0.7) 
36-40 2 (0.03) 11 (0.1) 13 (0.2) 38 (0.5) 
 
 
Table 4. Frequency distributions of the MELDEQ and deMELD scores for HCC 
patients at first listing and at last follow-up on the waitlist.  Numbers in each cell 
are the count and percentage of patients out of 7928 total HCC patients.  
 
To project dropout and transplant probabilities based on the proposed 
schemes, the same multistate model was constructed for non-HCC patients 
using analogous laboratory MELD score ranges, and the transplant hazard rates 
from the non-HCC model were substituted into the HCC models for groups in the 
same MELDEQ and deMELD ranges.  This is the same procedure that was used 
in the original paper describing the MELDEQ 15.  These were then used to project 
transplant probabilities using the Aalen-Johansen estimator 21,22.   
To compare equity of projected HCC dropout and transplant under the 
equivalent MELD models with that of non-HCC patients, matching of projected 
HCC transplant and dropout probabilities under each scheme to non-HCC 
probabilities was assessed graphically.  Projected dropout was also assessed 
numerically for each stratum.  The absolute value of the difference between non-
HCC probabilities and projected HCC dropout probabilities was calculated. 
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Similarly, the relative difference was calculated as a proportion of non-HCC 
probabilities.  These absolute and relative differences were then averaged over 
all times through one year.  To obtain an overall estimate of projected 
comparability to non-HCC probabilities for each score, an average of these 
absolute and relative differences was taken at each time, weighted by the 
proportion in each stratum of the number at risk at that time.  These results were 
then averaged over all times through one year.  Since the absolute value of these 
differences represents HCC dropout either exceeding or not reaching non-HCC 
dropout, a smaller value indicates better equality with non-HCC dropout 
probabilities. 
Using the described score ranges, differences in the way the two 
alternative scores classified patients were explored by comparing the values of 
patient covariates for those observations where the alternative score categories 
agreed with those observations where they did not.  The concordance index was 
also used to compare overall predictive accuracy for waitlist dropout 27 between 
the two scores.  Lastly, we compared post-transplant survival between the 
various risk groups as determined by both scores using Kaplan-Meier curves and 
Cox proportional hazard models.  
 
 
RESULTS 
A total of 7,928 HCC and 34,868 non-HCC patients were studied as in 
Chapter 2.  Table 4 shows the distributions of the two scores at initial listing and 
last follow-up.  The overall C-indices for HCC waitlist dropout were 0.586 (95% 
CI: 0.562, 0.61) for exception MELD scores, 0.653 (95% CI: 0.624, 0.682) for 
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laboratory MELD, 0.678 (95% CI: 0.649, 0.707) for MELDEQ and 0.664 (95% CI: 
0.635, 0.693) for deMELD.  In comparison, the C-index for non-HCC waitlist 
dropout was 0.832 (95% CI: 0.822, 0.842) for MELD.   
 To assess the agreement in actual dropout probabilities between non-
HCC patients and HCC patients stratified by the MELDEQ, Figures 6a and 7a 
compare actual dropout probabilities for HCC patients stratified by MELDEQ 
ranges to that of non-HCC patients in corresponding MELD ranges.  For the 
lower risk categories (scores <22) shown in 6a, the MELDEQ matches non-HCC 
dropout fairly well until about 6 months from entering a state and then begins not 
to reach non-HCC dropout probabilities, especially for the 16-18 and 19-21 score 
ranges.  As shown on Figure 7a, the actual dropout probability curve for the 
MELDEQ 22-24 group matches the corresponding non-HCC curve well at most 
times, but matching is poor for groups with MELDEQ scores above 24.  There is 
some matching for the 36-40 group but data are sparse in this range. 
A similar assessment of agreement in actual dropout probabilities was 
performed for the deMELD (Figures 8a and 9a).  The deMELD showed good 
matching through about eight months from entering a state for scores <22  
(Figure 8a). Matching of actual dropout probabilities to corresponding non-HCC 
ranges is somewhat better under the deMELD than the MELDEQ for scores less 
than 22.  Matching is poor under deMELD for groups with scores greater than 21 
(Figure 8a).  Again, data are sparse for the higher risk groups, especially as 
stratified by the MELDEQ. This can be seen in the numbers at risk shown in 
Figures 7a and 9a. 
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Projected dropout probabilities are increased beyond target non-HCC 
levels for groups in the lower risk ranges (MELDEQ and deMELD <16) under both 
alternative scores (see Figures 6b and 8b), though to a lesser degree for 
deMELD 12-15 (Figure 8b).  However, dropout would decrease for those with 
alternative MELD scores ≥22 (Figures 7b and 9b), to a lesser degree for 
MELDEQ 22-24.  Actual dropout is already lower than non-HCC for most of these 
strata (Figures 7a and 9a).  Actual and projected dropout probabilities appear 
especially low for deMELD ≥22 (Figures 9a and 9b).     
Table 5 displays absolute and relative differences by stratum and overall 
average difference (weighted by strata) between non-HCC dropout and projected 
HCC dropout under each equivalent MELD score if implemented.  Matching to 
non-HCC dropout probabilities is similar between the deMELD and the MELDEQ 
for equivalent scores <12, 16-18, and 31-35.  Matching is better for deMELD 
scores of 12-15 (absolute difference of 0.00647 vs. 0.01152 for MELDEQ) and 19-
21 (0.00564 vs 0.00745 for MELDEQ).  Matching is better for MELDEQ scores of 
22-24 (0.01178 vs. 0.04148 for deMELD), 25-30 (0.04693 vs. 0.06388 for 
deMELD), and 35-40 (0.06820 vs. 0.15135 for deMELD).  The weighted overall 
difference is very similar between the two scores. 
Projected transplant for both scores (Figures 6-9, panel d) shows better 
stratification based on risk level than actual transplant probabilities (Figures 6-9, 
panel c), especially for the lower risk groups, although lower than target non-
HCC probabilities for most groups.  The MELDEQ matches non-HCC transplant 
probabilities slightly better than the deMELD for equivalent scores 12-15 and 
similarly to the deMELD for scores <12 and 16-18.  The deMELD score matches 
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non-HCC transplant probabilities better than the MELDEQ for scores >18 and 
particularly scores ≥31.  However, neither score matches especially closely for 
the range of 19-30 (Figures 6-9, panel d).   
 
Equivalent 
MELD 
Score  
Range 
MELDEQ 
Difference from non-HCC 
Absolute             Relative 
deMELD 
Difference from non-HCC 
Absolute              Relative 
<12 0.01002 39.7% 0.01049 41.4% 
12-15 0.01152 29.8% 0.00647 18.4% 
16-18 0.00236 6.9% 0.00239 6.9% 
19-21 0.00745 9.5% 0.00564 9.4% 
22-24 0.01178 12.0% 0.04148 38.9% 
25-30 0.04693 37.4% 0.06388 50.4% 
31-35 0.09742 63.4% 0.09372 60.6% 
35-40 0.06820 35.9% 0.15135 75.8% 
Overall 0.01030 32.0% 0.01034 32.6% 
 
Table 5. Average absolute and relative differences between non-HCC and 
projected HCC dropout probabilities under MELDEQ or deMELD by range of each 
equivalent MELD score.  The absolute differences are the absolute values of the 
difference between the projected HCC dropout curves and non-HCC actual 
dropout curves depicted in Figures 6b, 7b, 8b and 9b. The relative differences 
are those absolute differences as a proportion of actual non-HCC dropout 
probabilities.  Smaller values indicate closer matching between the equivalent 
MELD range and the target non-HCC MELD range.  The overall differences 
weighted by number at risk in each stratum and averaged over all times through 
365 days are shown in the bottom row.  The number at risk is shown for 0, 3, 6 
and 9 months on Figures 6a, 7a, 8a and 9a, though for this calculation the 
number at risk at each time from 1 to 365 days was used. 
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Figure 6: Actual and projected time to dropout/transplant for lower-risk 
(MELDEQ<22) HCC patients stratified by MELDEQ score.  Time is from entry 
into the corresponding MELDEQ range for HCC patients or the MELD range for 
non-HCC patients.  Solid lines indicate probablity of transplant/dropout for HCC 
patients, whereas dashed lines indicate corresponding probability curves (actual 
only) for non-HCC patients. The number at risk for HCC patients at 0, 3, 6, and 9 
months is given in panel a.  The predictions pertain only to HCC patients; for 
non-HCC patients only actual probability curves are given.  
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Figure 7: Actual and projected time to dropout/transplant for higher-risk 
(MELDEQ≥22) HCC patients stratified by MELDEQ score.  Time is from entry 
into the corresponding MELDEQ range for HCC patients or the MELD range for 
non-HCC patients.  Solid lines indicate probablity of transplant/dropout for HCC 
patients, whereas dashed lines indicate corresponding probability curves (actual 
only) for non-HCC patients. The number at risk for HCC patients at 0, 3, 6, and 9 
months is given in panel a.  The predictions pertain only to HCC patients; for 
non-HCC patients only actual probability curves are given. 
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Figure 8: Actual and projected time to dropout/transplant for lower-risk 
(deMELD<22) HCC patients stratified by deMELD score.  Time is from entry 
into the corresponding deMELD range for HCC patients or the MELD range for 
non-HCC patients.  Solid lines indicate probablity of transplant/dropout for HCC 
patients, whereas dashed lines indicate corresponding probability curves (actual 
only) for non-HCC patients. The number at risk for HCC patients at 0, 3, 6, and 9 
months is given in panel a.  The predictions pertain only to HCC patients; for 
non-HCC patients only actual probability curves are given. 
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Figure 9: Actual and projected time to dropout/transplant for higher-risk  
(deMELD≥22) HCC patients stratified by deMELD score.  Time is from entry 
into the corresponding deMELD range for HCC patients or the MELD range for 
non-HCC patients.  Solid lines indicate probablity of transplant/dropout for HCC 
patients, whereas dashed lines indicate corresponding probability curves (actual 
only) for non-HCC patients. The number at risk for HCC patients at 0, 3, 6, and 9 
months is given in panel a.  The predictions pertain only to HCC patients; for 
non-HCC patients only actual probability curves are given. 
50 
Effect of Covariates on MELDEQ and deMELD 
Table 6 shows a cross-tabulation of how each observation on the waiting 
list was categorized by each alternative score.  Risk groups with MELDEQ and 
deMELD scores <19 had the most agreement between the two scores: the 
majority of observations placed in these categories by one score were also 
placed there by the other score.  Table 7 shows summaries of the contributing 
covariates for observations that were placed in the same category by both scores 
and Table 8 shows those that were categorized differently by the two alternative 
scores.  This comparison was made when less than half the observations 
assigned to a category by one alternative score were also assigned there by the 
other score.  For example, 411 observations had deMELD scores in the 36-40 
range, and 93 (22.6%) of these also had MELDEQ scores of 36-40 (see Table 6).  
Another 171 (41.6%) of them had MELDEQ scores of 25-30, so the covariates of 
these 93 observations with score agreement were compared with those of the 
171 observations with score disagreement. 
As shown in Tables 7 and 8, in groups where the deMELD category 
exceeded the MELDEQ category, less than half of observations had waitlist times 
of six months or more, with the exception of the highest risk group (MELDEQ = 
31-35 and deMELD = 36-40, n=147, Table 8). In contrast, for the groups in which 
the MELDEQ was at least as great as the deMELD score (outside of scores in the 
19-21 range), 71-94.4% of waitlist times were greater than 6 months.  The 
MELDEQ assigns 6.85 more points when waitlist time is at least six months, and 
the deMELD does not include a term for time on the waitlist.  Also, in the groups 
for where the deMELD category exceeded the MELDEQ category, all 
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observations had a maximum tumor size greater than 1 cm, which was not true 
for categories with MELDEQ ≥ deMELD.  A tumor size >1 cm adds 21.2 points to 
the deMELD score, compared to 1.194 points for each cm increase for the 
MELDEQ.   
No obvious differences were noted in this comparison for number of 
tumors or AFP, so the distribution of them in the dataset as a whole was 
examined.  For number of tumors, the deMELD assigns more points unless 
there is only 1 tumor or greater than 4 tumors, since the deMELD assigns 5.9 
points for ≥2 tumors and the MELDEQ assigns 1.438 points per tumor.  However, 
about 80% of observations in the dataset had only 1 tumor (note that each 
patient can have multiple observations).  Thus, for the majority of observations, 
the MELDEQ was assigning 1.438 points for number of tumors while the deMELD 
was assigning 0 points, which is not a large difference when considering the 
other factors. 
For AFP >1, the MELDEQ will assign more points than the deMELD, as the 
deMELD gains 5.9 points if AFP >400, and 0 points otherwise.  If AFP >400 this 
term will be at least 7.93 for the MELDEQ: (ln(401) = 5.99 so the AFP term for 
MELDEQ will be 5.99*1.324 = 7.93).  However, if ln(AFP)=0, neither score will 
gain points for AFP.  Less than 25% of the observations in each group compared 
had AFP levels >400, and less than 15% had ln(AFP) = 0. Thus, the MELDEQ 
assigned points (approximately 1 to 8) for AFP to most observations while the 
deMELD assigned 0 for most observations.  In the entire dataset only 1698 
(3.2%) of observations had AFP>400 and only 845 (1.6%) had ln(AFP)=0.  The 
median AFP in the dataset was 9, and the 75th percentile was 29, so half the 
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observations would receive less than 2.9 points, and the majority would be 
assigned less than 4.5 points by the MELDEQ for AFP. 
For the laboratory MELD, it was noted that in the groups studied where 
the deMELD category exceeded the MELDEQ category, none of the deMELD 
scores matched the laboratory MELD.  The converse was also true for the 
category in which MELDEQ exceeded deMELD, but only one such category was 
examined (Table 8).  This is not surprising since each score takes the maximum 
of the calculated score or the laboratory MELD (so a higher equivalent score 
might already exceed the laboratory MELD).  The deMELD assigns 1.9 points 
and the MELDEQ assigns 1.143 points for every 1 point increase in laboratory 
MELD. 
Of the groups compared for score agreement, waitlist time and maximum 
tumor size seemed to have the most effect, which is expected since these will 
generally account for the biggest differential in contributions to each score. 
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 deMELD Category  
MELDEQ 
Category <12 12-15 16-18 19-21 22-24 25-30 31-35 36-40 
Row 
Totals 
<12 
27189 
99.9% 
89.9% 24 2 0 0 0 0 0 
27215 
50.7% 
12-15 2552 
10640 
76% 
82.7% 789 13 1 0 0 0 
13995 
26.1% 
16-18 409 1608 
3269 
54.3% 
64% 342 
390 
6.5% 
31.8% 2 0 0 
6020 
11.2% 
19-21 57 543 
747 
23.6% 
14.6% 
1168 
36.9% 
60.8% 337 310 0 0 
3162 
5.9% 
22-24 12 55 261 297 
383 
22.3% 
31.2% 
530 
30.9% 
39.1% 176 0 
1714 
3.2% 
25-30 12 0 42 102 116 
480 
39.7% 
35.4% 
285 
23.6% 
52.1% 
171 
14.2% 
41.6% 
1208 
2.3% 
31-35 0 0 0 0 1 31 
80 
30.9% 
14.6% 
147 
56.8% 
35.8% 
259 
0.5% 
36-40 0 0 0 0 0 2 6 
93 
92.1% 
22.6% 
101 
0.2% 
Column 
Totals 
30231 
56.3% 
12870 
24% 
5110 
9.5% 
1922 
3.6% 
1228 
2.3% 
1355 
2.5% 
547 
1% 
411 
0.8% 53674 
 
Table 6: Cross tabulation of equivalent MELD score assignments by 
MELDEQ and deMELD.  The numbers in each cell are the number of HCC 
observations categorized by the deMELD score in the column heading and the 
MELDEQ score in the row heading followed by the row percent and column 
percent.  The row and column totals shown include the percent of total 
observations. Each individual patient can have multiple observations 
representing different follow up times on the waiting list.  The cells where scoring 
systems agree are green, and those selected for comparison where scores do 
not agree are red.
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     Comparison 
Covariate 
MELDEQ and deMELD=36-40 
n = 93 obs. 
MELDEQ and deMELD=31-35 
n = 80 obs. 
MELDEQ and deMELD=25-30 
n = 480 obs. 
Waitlist time 
+6.85 to MELDEQ if≥6 mo
85 (91.4% )≥6 mo 73 (91.3%) ≥6 mo 408 (85% )≥6 mo 
Max tumor size 
+21.2 to deMELD if>1cm
+1.194*size to MELDEQ
85 (91.4%) >1cm 
8 (8.6%) were 0 
Median size = 2.4 cm 
60 (75%) >1cm 
16(20%) were 0 
Median size =2.3 cm 
383 (79.8%) >1cm 
88(18.3%) were 0 
Median size = 2 cm 
Number of tumors 
+5.9 to deMELD if ≥ 2
+1.438*no. to MELDEQ
45 (48.4%) ≥ 2 
none were 0 
Median no. = 1 
12 (15%) ≥ 2 
none were 0 
Median no. = 1 
134 (27.9%) ≥ 2 
none were 0 
Median no. = 1 
AFP or ln(AFP) 
+5.9 to deMELD if >400
+1.324*ln(AFP) to MELDEQ
21 (22.6%) w/AFP>400 
1(1.1%)w/ln(AFP)=0 
Median n(AFP)=2.1 
14 (17.5%) w/AFP>400 
none w/ln(AFP)=0 
Median ln(AFP)=3 
54 (11.3%) w/AFP>400 3 
(<1%) w/ln(AFP)=0 
Median ln(AFP)=2.6 
Lab MELD 
+1.9*MELD to deMELD
+1.143*MELD to MELDEQ
Range 22-40 
12(12.9%)w/MELD=deMELD 
13(14%) w/MELD =MELDEQ 
Range 20-35 
20(25%)w/MELD =deMELD 
12(15%) w/MELD=MELDEQ 
Range 16-30 
97(20.2%)w/MELD=deMELD 
73(15.2%)w/MELD=MELDEQ 
      Comparison 
Covariate 
MELDEQ and deMELD=22-24 
n = 383 obs. 
MELDEQ and deMELD=19-21 
n = 1168 obs. 
Waitlist time 
+6.85 to MELDEQ if≥6 mo
272 (71%) ≥6 mo 391(33.5%) ≥6 mo 
Max tumor size 
+21.2 to deMELD if>1cm
+1.194*size to MELDEQ
176 (46%) >1cm 
186(48.6%) were 0 
Median size = 0.8 cm 
790(67.6%)>1 cm 
342(29.4%)) were 0 
Median size = 2 cm 
Number of tumors 
+5.9 to deMELD if ≥ 2
+1.438*no. to MELDEQ
96 (25.1%) ≥ 2 
none were 0  
Median no. = 1 
109(9.3%)≥ 2 
20(1.7%) were 0 
Median no. = 1 
AFP or ln(AFP) 
+5.9 to deMELD if >400
+1.324*ln(AFP) to MELDEQ
11 (2.9%) w/AFP>400 
14 (3.7%) w/ln(AFP)=0 
Median ln(AFP)=1.8 
35(3%) w/AFP>400 
35(3%) w/ln(AFP)=0 
Median ln(AFP)=1.6 
Lab MELD 
+1.9*MELD to deMELD
+1.143*MELD to MELDEQ
Range 14-24 
207(54%)w/MELD=deMELD 
178(46.5%)w/MELD=MELDEQ 
Range 13-21 
378(32.4%) w/MELD= deMELD 
890(76.2%) w/MELD = MELDEQ 
Table 7. Effect of covariates with score agreement. 
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     Comparison  
Covariate 
MELDEQ=31-35,deMELD=36-40 
n = 147 obs. 
MELDEQ=25-30, deMELD=36-40 
n = 171 obs.  
MELDEQ=25-30,deMELD=31-35  
n = 285 obs. 
Waitlist time 
+6.85 to MELDEQ if≥6 mo
109(74%)≥6 mo 9 (5.3%)≥6 mo 130 (45.6%)≥6 mo 
Max tumor size 
+21.2 to deMELD if>1cm
+1.194*size to MELDEQ
147(100%) >1 cm 
None were 0  
Median size=2 cm 
171(100%) >1cm 
None were 0 
Median size = 2.1 cm 
285(100%) >1cm 
None were 0 
Median size = 2.2 cm 
Number of tumors 
+5.9 to deMELD if ≥ 2
+1.438*no. to MELDEQ
61(41.5%)≥ 2 
None were 0 
Median no. = 1 
109 (63.7%) ≥ 2 
2 (1.2%) were 0 
Median no. = 2 
102 (35.8%) ≥ 2 
None were 0 
Median no. = 1 
AFP or ln(AFP) 
+5.9 to deMELD if >400
+1.324*ln(AFP) to MELDEQ
9(6.1%) w/AFP>400 
15(10.2%) w/ln(AFP)=0 
Median ln(AFP)=1.8 
3 (1.8%) w/AFP>400 
6 (3.5%) w/ln(AFP)=0 
Median ln(AFP)=2.2 
22(7.7%) w/AFP>400 
20 (7%) w/ln(AFP)=0 
Median ln(AFP)=2.3 
Lab MELD 
+1.9*MELD to deMELD
+1.143*MELD to MELDEQ
Range 22-35 
0 w/MELD = deMELD 
29(19.7%) w/MELD=MELDEQ 
Range 22-30 
0 w/MELD = deMELD 
153 (89.5%) w/MELD=MELDEQ 
Range 20-27 
0 w/MELD = deMELD 
109(38.2%) w/MELD=MELDEQ 
 Comparison         
Covariate 
MELDEQ=22-24,deMELD=25-30 
n = 530 obs. 
MELDEQ=16-18, deMELD=22-24 
n = 390 obs. 
MELDEQ=19-21,deMELD=16-18 
n = 747 obs. 
Waitlist time 
+6.85 to MELDEQ if≥6 mo
120 (22.6%)≥6 mo 14(3.6%) ≥ 6 mo 705 (94.4%)≥6 mo 
Max tumor size 
+21.2 to deMELD if>1cm
+1.194*size to MELDEQ
530(100%) >1cm 
None were 0 
Median size = 2.4 cm 
390(100%) >1cm 
None were 0 
Median size = 2 cm 
682(91.3%) >1cm 
61 (8.2%) were 0 
Median size = 2.2 cm 
Number of tumors 
+5.9 to deMELD if ≥ 2
+1.438*no. to MELDEQ
91 (17.2%) ≥ 2 
1 (0.2%) was 0 
Median no. = 1 
382(97.9%)≥ 2 
None were 0 
Median no. = 2 
154 (20.6%) ≥ 2 
8 (1.1%) were 0 
Median no. = 1 
AFP or ln(AFP) 
+5.9 to deMELD if >400
+1.324*ln(AFP) to MELDEQ
22 (4.2%) w/AFP>400 
33 (6.2%) w/ln(AFP)=0 
Median ln(AFP)=1.6 
19(4.9%)w/AFP>400 
6(1.5%) w/ln(AFP)=0 
Median ln(AFP)=2.1 
22 (2.9%) w/AFP>400 
11 (1.5%) /ln(AFP)=0 
Median ln(AFP)=2.6 
Lab MELD 
+1.9*MELD to deMELD
+1.143*MELD to MELDEQ
Range 16-24 
0 w/MELD = deMELD 
347(65.5%)w/MELD=MELDEQ 
Range 14-18 
0 w/MELD = deMELD 
345(88.5%)w/MELD=MELDEQ 
Range 11-18 
585(78.3%) w/MELD=deMELD 
0 w/MELD=MELDEQ 
Table 8. Effect of covariates without score agreement.
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Post-Transplant Survival 
Post-transplant survival was compared for alternative MELD scores in 
ranges 6-15, 16-21, 22-30, and 31-40; see Figure 10.  A significant difference 
was seen between the lowest risk group and the 22-30 group under both scores 
(p=0.007, MELDEQ; p=0.015, deMELD; see Table 9).  For the MELDEQ, this 22-
30 group has a steady decrease in survival rate for about two years and then 
nearly levels off, while for the deMELD this group has a slightly more gradual 
decrease over time.  The highest risk group had a higher survival rate for the first 
year and then decreased quickly, while the highest risk group for deMELD had a 
sharper decrease in the first 1 ½ months and then decreased gradually over 
time.  Data in this highest risk group were sparse under both scores as seen in 
the numbers at risk.   
Cox proportional hazard models were also fit to predict post-transplant 
survival by these risk strata.  The hazard ratio (HR) for the MELDEQ 22-30 group 
was 1.588 (1.132, 2.228, p=0.007), and 1.477 (1.078, 2.022, p=0.015) for 
deMELD 22-30 group, relative to the 6-15 groups.  The HR’s were not significant 
among the other strata as shown in Table 9, and proportional hazards 
assumptions were met (global chi-squared 5.669, 3 df, p=0.129 for MELDEQ; 
global chi-squared 3.7, 3 df, p=0.296 for deMELD) 28.  
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Figure 10. Post-transplant survival for HCC patients stratified by MELDEQ 
and deMELD ranges.  Kaplan-Meier survival curves for HCC patients with the 
indicated alternative MELD score ranges at last follow up prior to transplant.  The 
number at risk in each stratum is shown for 0, 1, 2, and 3 years at the bottom of 
each panel. 
MELDEQ 
Group HR 95% CI p-value
<16 reference reference reference 
16-21 1.141 0.937, 1.389 0.189 
22-30 1.588 1.132, 2.228 0.007 
31-40 1.175 0.293, 4.712 0.820 
deMELD 
Group HR 95% CI p-value
<16 reference reference reference 
16-21 1.052 0.839, 1.320 0.661 
22-30 1.477 1.078, 2.022 0.015 
31-40 1.386 0.690, 2.787 0.359 
Table 9.  Hazard Ratios for Post-Transplant Survival from Cox Proportional 
Hazard Models 
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DISCUSSION 
Previous research has demonstrated that scheduled progression of 
exception points is not an equitable method of prioritizing liver transplant 
between HCC and non-HCC patients.  While the current allocation scheme 
implementing a six-month delay prior to granting exception points should improve 
equity of outcomes, reverting to scheduled exception point progression may still 
advantage HCC patients after six months and treats all HCC patients as having 
the same dropout risk regardless of tumor characteristics or laboratory MELD as 
discussed in Chapter 2.  Hence it is unknown whether the current six-month 
delay provides the final solution for equitable transplant for HCC and non-HCC 
patients, and in the interim it is instructive to evaluate potential candidates for 
equivalent MELD scores to assess their strengths and weaknesses.  The 
MELDEQ and deMELD models both show improvement over scheduled 
progression of exception points, with better stratification of dropout and 
transplant probabilities.  Overall numerical comparisons of the two scores slightly 
favored the MELDEQ for dropout prediction, with C-indices of 0.678 and 0.664 
respectively.  However, this result was not statistically significant as 95% CIs for 
both C-indices overlapped.  Both scores match actual dropout probabilities 
comparably to laboratory MELD for non-HCC patients fairly well for patients with 
alternative MELD scores <22, though the deMELD remains more closely aligned 
for a longer time period than the MELDEQ (approximately 8 months vs 6 months) 
once a patient enters a given score range.  Neither score matches actual dropout 
accurately for the higher risk groups with the exception of the MELDEQ for those 
with scores 22-24.   
59 
Differences in projected HCC dropout and non-HCC dropout were similar 
overall between the MELDEQ and the deMELD.  However, the projected dropout 
tended to be closer to non-HCC dropout under the deMELD for equivalent scores 
<22 and closer under the MELDEQ for equivalent scores ≥22. 
A problem for both scores is that dropout would increase beyond non-
HCC levels for groups with equivalent scores <16 if prioritization were based on 
them.  However, the average difference over one year between projected 
dropout for these groups and actual dropout of analogous non-HCC groups is 
around 0.01 – near zero in the first few months since entering a given risk strata 
but increasing over time.   
In contrast to the <16 groups, dropout is projected to decrease for higher 
risk groups, especially under the deMELD.  This is because actual transplant and 
dropout probabilities for the higher risk groups are largely lower than those for 
corresponding non-HCC risk groups, so transplanting them at a higher rate to 
match non-HCC rates would be expected to decrease their dropout further.   
In the original paper describing the MELDEQ 15, actual dropout and 
transplant probabilities were depicted similarly to Figures 6a, 6c, 7a and 7c in 
this writing. These probabilities appear to have decreased in the newer data.  A 
possible explanation may be that people are able to wait longer than they could 
in the past for transplant without dropping out, perhaps due to improvement in 
other therapies or patient management.  Both scores can indirectly account for 
effects from other therapies (for example, ablation) if they are reassessed over 
time, since if a patient receives ablation and their maximum tumor size is 
reduced, their MELDEQ and deMELD scores would also be reduced accordingly.  
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This consideration was also discussed in the paper describing the deMELD 13.  
Under the scheduled exception point progression, which resumes after six 
months with the recently implemented six-month delay, such a patient would 
receive the same number of exception points at each three-month interval as a 
patient who did not have another therapy (or any HCC patient who remained 
eligible for exception points).  However, as ablation and other treatments are not 
covariates in either of the models evaluated, we did not directly look at their 
effects in this study.   
Both scores improve risk stratification and allow for more equitable 
transplant probabilities. Although they do not match non-HCC transplant 
probabilities perfectly, they are much closer than under scheduled exception 
point progression for most risk groups.  One notable difference between the two 
scores is that the deMELD identifies more patients in higher risk (≥22) categories 
at listing.  The main reasons for this are 1) the MELDEQ assigns 6.85 more points 
after six months on the list and 2) the deMELD gives much greater weight to 
tumor size (21.2 points for tumors >1cm vs. 1.194 points for each cm for the 
MELDEQ).  The deMELD also uses discrete cutoff points for most of the HCC 
covariates while the MELDEQ uses continuous values.  Thus, the deMELD may 
be more “stable” compared to the MELDEQ for higher risk groups, in that a 
change in score requires a larger change in the covariates than it would for the 
MELDEQ. 
Projected transplant under the deMELD matches non-HCC probabilities 
well for these higher risk groups.  However, a potential concern with prioritizing 
higher risk HCC patients is earlier transplantation of patients with more 
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aggressive tumors who may have poorer outcomes post-transplant.  We did find 
that post-transplant survival is significantly lower for the 22-30 equivalent MELD 
score group compared to the lowest risk group for both scores, but no significant 
differences were found between the other risk groups.  Adjustment of both scores 
may be warranted to avoid transplanting those at high risk for recurrence.  This 
concern was mentioned in the original publication of the deMELD as well, and 
they suggested the possibility of using a 3-6 month waiting time along with their 
score 13.  Potential causes of lower post-transplant survival in the 22-30 group 
(e.g. recurrence vs. graft failure or other causes) were not investigated in this 
study.  In addition, HCC dropout is already lower than that for non-HCC patients 
for groups with scores ≥22, except for MELDEQ >35 after about 7 months from 
reaching this score.  The lower dropout probabilities for scores in this range 
suggest that perhaps lower equivalent MELD scores could be more appropriate 
for some patients in this group.  A possible area for future research could be 
simply modeling dropout of HCC and non-HCC patients based on laboratory 
MELD alone, and equating dropout hazards or probabilities to determine an 
appropriate adjustment to the MELD score for HCC patients.   
One limitation of this study is that total risks/benefits between dropout, 
transplant, and post-transplant survival were not considered.  Other investigators 
have discussed this 16,19,20, and overall utility (combined dropout/post-transplant 
survival) is included in the model by Vitale et al14.  Comparing that approach with 
those studied in this paper is another potential area for future research.  
However, the evaluation criteria for comparing the Vitale et al. score with the 
MELDEQ/deMELD is difficult to determine given the differences in objectives 
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between the studies.  The covariates included in the models studied here have 
also been studied as prognostic indicators for post-transplant outcomes, 
particularly AFP 4,19,29.  Another limitation of the current study is that while setting 
time zero as the first time a patient enters a given risk category may be of greater 
clinical interest, it does not allow for projections for non-HCC patients under the 
proposed scoring schemes.  However, comparison to actual non-HCC outcomes 
is useful for assessing how well the equivalent scores would improve equity 
between non-HCC and HCC transplant and dropout rates. 
A strong point of this study is that although several models incorporating 
HCC characteristics for transplant prioritization have been proposed, no previous 
studies were identified that compared projected outcomes between two proposed 
HCC-specific models as well as with actual practice.  While the current results do 
not provide a clear-cut answer to which of these scores better prioritizes HCC 
patients, they do highlight strengths and weaknesses of each which can provide 
direction for ongoing work on an HCC prioritization score. 
In summary, the MELDEQ and deMELD would both improve equity in 
transplant access between HCC and non-HCC patients compared to scheduled 
progression.  While overall matching of projected dropout probabilities with non-
HCC levels is nearly identical between the two scores, the deMELD does a better 
job of matching the lower risk scores ≤21.  An advantage of the MELDEQ is that it 
“builds in” additional points at six months waitlist time and thus is a natural 
counterpart to the current six-month delay in granting exception points.  For the 
deMELD, an advantage is that projected transplant probabilities are relatively 
close to those of non-HCC patients in most analogous MELD score ranges.  
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Also, since the deMELD uses discrete cutoff points for most of the HCC 
covariates the score is unlikely to change dramatically over time.  Disadvantages 
of both scores include projected dropout probabilities that exceed non-HCC 
probabilities for those with alternative MELD scores <16, and potential for 
prioritizing higher risk patients with poorer post-transplant survival and lower 
actual dropout rates.  Thus further calibration and development of both scores is 
recommended before their implementation.
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CHAPTER 4 
SUMMARY 
Improvement in prioritization of liver transplant for patients with HCC is 
needed, as scheduled progression of exception points does not consider tumor 
characteristics and treats all HCC patients similarly regardless of their dropout 
risk.  The possible solutions evaluated here do offer improvement, but each has 
limitations. 
While the newly implemented six-month delay in assigning exception 
points to HCC patients will help address the disparity in transplant rates between 
HCC and non-HCC patients, the improvement will mostly be seen for the first six 
months as discussed in Chapter 2.  After this time, transplant probabilities for 
HCC patients will quickly return to exceeding those for non-HCC patients and 
also become similar among HCC dropout risk strata.  
The MELDEQ would help equalize dropout probabilities between HCC and 
non-HCC patients over time, but would reduce transplant probabilities for HCC 
patients below those of non-HCC patients.  Use of the MELDEQ beginning at six 
months on the waiting list is projected to match non-HCC transplant probabilities 
well with very good risk stratification but may increase HCC dropout, especially 
for the highest risk group.   
Comparison of the MELDEQ and the deMELD scores, as shown in Chapter 
3, again revealed that both scores show promise but are projected to increase 
dropout probabilities beyond those of non-HCC patients in the same ranges for 
65 
patients with equivalent scores <16.  However, patients in this group currently 
have low dropout risk, and the projected increase above non-HCC dropout 
probabilities is not large for either score.  For the higher risk groups (equivalent 
scores of at least 22), both scores would make transplant probabilities more 
equitable with non-HCC patients but then decrease dropout below that of non-
HCC patients in the same risk groups, particularly for the deMELD.  The deMELD 
assigns points heavily for tumor size, so a possible disadvantage is that patients 
scored higher by deMELD could be at risk for post-transplant recurrence.  This 
study did find that patients in some high-risk groups may have worse post-
transplant survival.  This is also discussed in the original paper for the deMELD 
and the authors suggest possibly using a waiting period before use of the 
score13.  The MELDEQ assigns more points for waitlist time of at least six months, 
but does not weight tumor size as heavily.  Thus either score may have potential 
for use in conjunction with the six-month delay or after six months waitlist time.  
Alternatively, perhaps after further calibration, a score such as the deMELD or 
the MELDEQ could replace the scheduled progression altogether.  Further 
evaluation and research of these scores and other alternative prioritization 
schemes could aid in such calibration and refinement. 
The methods of evaluating these prioritization schemes in the preceding 
chapters had several strengths and weaknesses.  Somewhat different projection 
methods were used to evaluate the six-month delay and to compare the two 
equivalent MELD scores.  Because relatively few patients are classified in the 
higher risk categories at listing, taking time zero as time a patient first enters a 
risk category, as described in Chapter 3, was more appropriate for comparing the 
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two equivalent MELD scores.  A limitation of using time first entering a risk state 
as time zero is that interpretation and comparison among risk groups may be 
less straightforward.  Also, the projection method to include effects on non-HCC 
patients was not employed in the comparison study since it uses total number of 
organs transplanted at a given time and the proportions going to each stratum of 
HCC and non-HCC patients at a given time.  Thus, the projections for the 
comparison in Chapter 3 only included those for HCC patients.  One strength of 
this approach is that it can be more relevant clinically to determine a patient’s 
probability of dropout from the time they develop a certain set of values of the 
relevant covariates.   
For evaluating the six-month delay in Chapter 2, it was necessary to 
define time zero as the initial waitlist time, since the delay of six months is 
defined as time since listing.  A limitation of using time since listing is that data 
can be sparse in the higher risk categories as mentioned earlier, since relatively 
few patients are classified in these higher risk groups at listing.  An attempt to 
account for this was made by combining the higher risk categories for the six-
month delay/MELDEQ comparison.  The projection method to include non-HCC 
patients has limitations as mentioned earlier in that it does not reflect calendar 
time for the whole group, so the estimates of available organs at each time may 
not be completely realistic.  However, since prioritization schemes were 
compared using the same methods, it is still a useful comparison of the 
schemes.  Overall, a strength of both studies described here is that projections 
were used to evaluate outcomes for HCC and non-HCC patients as whole 
groups as well as among different risk strata under three different prioritization 
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methods.  Additionally, this study identified strengths and weakness of each 
scheme that may help guide further research and improvement of the scores. 
The MELDEQ and the deMELD were selected for comparison for this 
project because they were derived most similarly, but evaluation of additional 
scoring methods, such as the method by Vitale et al that includes a utility score14 
could be an area for future research.  Evaluation of such scores using a model 
that considered both waitlist dropout and post-transplant mortality could be useful 
for determining net benefit.  Additionally, further calibration of a score similar to 
the MELDEQ or deMELD could be attempted by using simulated data to equate 
dropout and/or transplant outcomes between HCC and non-HCC patients.  
Further, exploration of new covariates that could influence waitlist dropout and 
post-transplant outcomes, such as other HCC-related biomarkers or response to 
other therapies for HCC, could be beneficial.  Alternatively, equating dropout risk 
between HCC and non-HCC patients with MELD as the only covariate may help 
determine an appropriate and simple adjustment to the laboratory MELD for HCC 
patients. 
In conclusion, transplant prioritization has not been equitable between 
HCC and non-HCC patients.  Potential improvement has been made with 
implementing the six-month delay though it still may advantage HCC patients 
after 6 months.  Possible solutions have been studied and proposed through 
alternative scoring schemes.  While these improvements represent progress in 
decreasing this disparity, more progress is needed and further research on HCC-
specific prioritization methods could help address this need.
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